Journal · Repair
Leaky Gut and Systemic Inflammation: The Peptides That Protect the Gut Lining
The short answer
The gut lining is a single layer of cells between what you eat and your bloodstream. When the seals between those cells loosen, bacterial fragments get through and switch on inflammation throughout the body, not just in the gut. That inflammation then slows repair everywhere else. BPC-157 and KPV are the two peptides most often discussed for protecting the lining.
Questions this article answers
The largest immune surface in your body
Section 2.6 of Regenerative Resilience starts with scale. The gastrointestinal mucosa alone covers an estimated 300 to 400 square metres, which makes it the biggest area of immune surveillance in the body. The barrier itself is one cell thick. It has to let nutrients in and keep microbes and their by-products out, all day, every day.
When that barrier holds, the local immune system handles what it meets quietly. When it fails, through inflammation, dysbiosis or direct injury, what should stay in the gut ends up in the circulation.
What “leaky gut” actually means
The medical term is intestinal hyperpermeability. The cells lining the gut are joined by tight junctions, and when those junctions are disrupted, material leaks between the cells.
The most important thing that leaks is lipopolysaccharide (LPS), a component of bacterial cell walls. LPS travels to the liver through the portal vein, triggers TLR4 receptors there, and drives production of inflammatory cytokines that circulate body-wide. The book links this chain to the low-grade chronic inflammation seen in metabolic disease, autoimmune conditions and “inflammaging”.
A fair note on the science: a 2019 review in Gut found that increased permeability is real and measurable in humans, but tests aren’t standardised and cause and effect is still being worked out for many conditions (reference 1). “Leaky gut” is a genuine mechanism, not a diagnosis that explains everything.
Why a gut problem slows healing somewhere else
This is the part most people miss. The inflammation driven by a leaky barrier doesn’t stay in the gut. It raises the background inflammatory load throughout the body, and the same load that stalls repair in a tendon or joint. Someone rehabbing a shoulder with an untreated gut barrier problem is trying to heal in a hostile environment. (Our post on immune rules for peptide protocols explains why that matters.)
The microbiome is part of the immune system
The gut hosts roughly 38 trillion microorganisms, and they are deeply wired into immune regulation. Friendly bacteria send the signals that keep immune responses in proportion. Two landmark 2013 studies show how:
- Short-chain fatty acids made by gut bacteria regulate the colon’s regulatory T cells, the cells that keep inflammation in check (reference 3).
- A selected mix of Clostridia strains from human gut bacteria was enough to induce regulatory T cells and reduce colitis in mice (reference 4).
Dysbiosis, a disrupted microbial community, weakens these signals, loosens tight junctions and tilts the gut toward inflammation. The effects spread well beyond digestion.
Where peptides fit
BPC-157
The book describes BPC-157 as having one of the strongest preclinical records for gut lining repair of any compound it covers. It began as a fragment of a protein found in gastric juice, and animal research reports effects on blood flow to the lining, the movement of epithelial cells to close damage, and local anti-inflammatory signalling (reference 5). Human evidence is very limited. Full details are in our BPC-157 profile.
KPV
KPV is a three-amino-acid fragment of alpha-MSH. It damps NF-kB, the switch behind many inflammatory genes. In mouse colitis models, KPV was absorbed by gut cells through the PepT1 transporter and reduced intestinal inflammation (reference 2). Human data are lacking.
What peptides don’t do
The book is direct about this: none of its compounds targets the microbiome itself. The reasoning is indirect. Restoring the barrier lowers the inflammatory input, which gives the microbial community better conditions to normalise. Diet, fibre and medical care for underlying gut disease remain the main levers for the microbiome.
Questions people ask
Does BPC-157 heal leaky gut?
There’s no human clinical trial showing that it does. Animal studies show strong effects on gut lining repair (reference 5), and Regenerative Resilience (pp. 69–70) considers it a core compound for barrier-related inflammation. Anyone with gut symptoms should get a medical assessment, since conditions such as coeliac disease and IBD need specific treatment.
What is KPV peptide used for?
It is researched mainly for inflammation, especially in the gut and skin. Its best-known study found reduced intestinal inflammation in mice (reference 2). In July 2026 an FDA advisory committee recommended KPV for the list of substances pharmacies may compound, a non-binding step (reference 6). It is not FDA approved.
Can leaky gut cause inflammation throughout the body?
That is the proposed mechanism: bacterial LPS crossing a weakened barrier and triggering inflammation via the liver. Research supports the mechanism, while its role in specific diseases is still being clarified (reference 1).
What are the best peptides for leaky gut?
BPC-157 and KPV are the two most studied for gut barrier and gut inflammation, both mostly in animals. “Best” depends on whether the main problem is barrier damage or inflammatory signalling, which is the distinction the book’s framework is built around.
Where this comes from in our books
This article is the plain-language version. The book sections below go further, with full mechanism detail, evidence tiers and how each idea fits a complete protocol. Page numbers refer to the print editions.
Regenerative Resilience
Section 2.6, The Mucosal Immune System and Barrier Integrity · pp. 68–70
Regenerative Resilience
Section 9.4, case model: Gastrointestinal Mucosal Restoration · pp. 303–307
Read next
Put the framework to work
The free Protocol Builder applies the same category-first logic as the books, built from the same compound database.
Open the Protocol BuilderSee the book seriesReferences
- Camilleri M. Leaky gut: mechanisms, measurement and clinical implications in humans. Gut. 2019;68(8):1516–1526. View source
- Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178. View source
- Smith PM, Howitt MR, Panikov N, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341(6145):569–573. View source
- Atarashi K, Tanoue T, Oshima K, et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature. 2013;500(7461):232–236. View source
- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612–1632. View sourceCited in Regenerative Resilience (p. 348)
- National Community Pharmacists Association. FDA advisory committee nominates six peptides for pharmacies to compound. July 31, 2026. View source
How this article is maintained. Research and regulatory status change. We review our articles against current sources and update them as new information becomes available; the date at the top shows the last review.
Educational information only, not medical advice. Nothing in this article is a recommendation to use any compound or a dosing guide. Talk to a qualified clinician before starting, stopping or combining any compound.